{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:08:45Z","timestamp":1781845725685,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602901"],"award-info":[{"award-number":["2022YFC3602901"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYGD23001"],"award-info":[{"award-number":["ZYGD23001"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3602902"],"award-info":[{"award-number":["2022YFC3602902"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.urolonc.2026.111034","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:43:53Z","timestamp":1771361033000},"page":"111034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Jianjun","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengni","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-5467","authenticated-orcid":false,"given":"Yige","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2026.111034_bib0001","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111034_bib0002","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update","volume":"87","author":"Masson-Lecomte","year":"2025","journal-title":"Eur Urol"},{"issue":"10364","key":"10.1016\/j.urolonc.2026.111034_bib0003","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111034_bib0004","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111034_bib0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.6004\/jnccn.2020.7539","article-title":"Integration of immunotherapy into the treatment of advanced urothelial carcinoma","volume":"18","author":"Ghatalia","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111034_bib0006","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111034_bib0007","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR inhibition in urothelial carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111034_bib0008","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with Human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111034_bib0009","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111034_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cells11050803","article-title":"Antibody-drug conjugates in urothelial carcinoma: a new therapeutic opportunity moves from bench to bedside","volume":"11","author":"Ungaro","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111034_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111034_bib0012","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.111034_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111034_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100637","article-title":"Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: results of a phase 2 study","volume":"6","author":"Yan","year":"2025","journal-title":"Med"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111034_bib0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00345-025-05544-1","article-title":"Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma","volume":"43","author":"Yao","year":"2025","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111034_bib0016","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12885-025-14154-4","article-title":"RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2026.111034_bib0017","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111034_bib0018","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen","year":"2018","journal-title":"J Med Libr Assoc"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111034_bib0019","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2020.12.017","article-title":"A modified Newcastle-Ottawa scale for assessment of study quality in genetic urological research","volume":"79","author":"Norris","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111034_bib0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jrsm.53","article-title":"Comparison of statistical inferences from the DerSimonian-Laird and alternative random-effects model meta-analyses - an empirical assessment of 920 Cochrane primary outcome meta-analyses","volume":"2","author":"Thorlund","year":"2011","journal-title":"Res Synth Meth"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111034_bib0021","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s12672-025-02362-0","article-title":"Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111034_bib0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12967-025-06237-4","article-title":"The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study","volume":"23","author":"Ge","year":"2025","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111034_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102093","article-title":"RC48-Antibody-drug conjugate in metastatic urothelial carcinoma: a multicenter real-world study in China","volume":"22","author":"Chen","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.111034_bib0024","article-title":"Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.urolonc.2026.111034_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1230395","article-title":"Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111034_bib0026","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00262-023-03419-1","article-title":"HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"10.1016\/j.urolonc.2026.111034_bib0027","doi-asserted-by":"crossref","first-page":"21159","DOI":"10.1002\/cam4.6680","article-title":"Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: a multicenter, retrospective clinical study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"issue":"23","key":"10.1016\/j.urolonc.2026.111034_bib0028","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab Vedotin plus Toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.111034_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251395928","article-title":"Efficacy and safety of a novel treatment scheme of RC48-ADC plus PD-1 inhibitors in metastatic urothelial carcinoma: a multicenter real-world study","volume":"17","author":"Lin","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111034_bib0030","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1186\/s12885-025-14870-x","article-title":"Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111034_bib0031","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00262-025-04154-5","article-title":"The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study","volume":"74","author":"Ng","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111034_bib0032","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12894-025-01960-y","article-title":"Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111034_bib0033","first-page":"165","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111034_bib0034","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111034_bib0035","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241297079","article-title":"Antibody-drug conjugates in patients with advanced\/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis","volume":"16","author":"Michelon","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.urolonc.2026.111034_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"17","key":"10.1016\/j.urolonc.2026.111034_bib0037","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111034_bib0038","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111034_bib0039","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.111034_bib0040","article-title":"Nectin-4 positivity in genitourinary malignancies: a systematic review","volume":"8","author":"Crupi","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"19","key":"10.1016\/j.urolonc.2026.111034_bib0041","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111034_bib0042","article-title":"HER2 and urothelial carcinoma: current understanding and future directions","author":"Raggi","year":"2025","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2026.111034_bib0043","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1200\/JCO.2025.43.5_suppl.828","article-title":"Molecular subtypes, NECTIN4\/HER2 expression, and clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) or muscle invasive bladder cancer (MIBC): exploratory analyses from JAVELIN bladder 100 and the tempus database","volume":"43","author":"Eckstein","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111034_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102340","article-title":"Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours","volume":"104","author":"Crucitta","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111034_bib0045","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.urolonc.2026.111034_bib0046","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: a SCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111034_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"24","key":"10.1016\/j.urolonc.2026.111034_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245721","article-title":"The genomic landscape of urothelial carcinoma with high and low ERBB2 expression","volume":"15","author":"Hadadi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111034_bib0049","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/03008916231186178","article-title":"A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients","volume":"110","author":"Ye","year":"2024","journal-title":"Tumori"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111034_bib0050","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1016\/j.asjsur.2024.04.161","article-title":"Discordance of HER2 expression in primary and recurrent\/metastatic urothelial carcinoma in the upper tract","volume":"47","author":"Ye","year":"2024","journal-title":"Asian J Surg"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:02:15Z","timestamp":1777608135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1078143926000451"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111034","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111034"}}